Tam Vincent H, Preston Sandra L, Drusano G L
Division of Clinical Pharmacology, Ordway Research Institute, Albany Medical College and New York State Department of Health, Albany, New York 12208, USA.
Antimicrob Agents Chemother. 2003 Sep;47(9):2888-91. doi: 10.1128/AAC.47.9.2888-2891.2003.
Generation of pharmacodynamic relationships in the clinical arena requires estimation of pharmacokinetic parameter values for individual patients. When the target population is severely ill, the ability to obtain traditional intensive blood sampling schedules is curtailed. Population modeling guided by optimal sampling theory has provided robust estimates of individual patient pharmacokinetic parameter values. Because of the wide range of parameter values seen in this circumstance, it is important to know how the range of parameter values in the population affects the timing of the optimal samples. We describe a new, simple technique to obtain optimal samples for a population of patients. This technique uses the nonparametric distribution associated with a nonparametric adaptive grid population pharmacokinetic analysis. We used the distribution from an analysis of 58 patients receiving levofloxacin for nosocomial pneumonia at a dose of 750 mg. The collection of parameter vectors and their associated probabilities were entered into a D-optimal design evaluation by using ADAPT II. The sampling times, weighted for their probabilities, were displayed in a frequency histogram (an expression of how system information varies with time for the population). Such an explicit expression of the time distribution of information allows rational sampling design that is robust not only for the population mean vector, as in traditional D-optimal design theory, but also for large portions of the total population. For levofloxacin, one reasonable six-sample design would be 1.5, 2, 2.25, 4, 4.75, and 24 h after starting a 90-min infusion. Such sampling designs allow informative population pharmacokinetic analysis with precise and unbiased estimates after the maximal a posteriori probability Bayesian step. This allows the highest probability of delineating a pharmacodynamic relationship.
在临床领域建立药效学关系需要估算个体患者的药代动力学参数值。当目标人群病情严重时,获取传统密集血样采集时间表的能力会受到限制。以最优采样理论为指导的群体建模提供了个体患者药代动力学参数值的可靠估算。由于在这种情况下会出现参数值范围广泛的情况,了解群体中参数值范围如何影响最优样本的采集时间很重要。我们描述了一种为患者群体获取最优样本的新的简单技术。该技术使用与非参数自适应网格群体药代动力学分析相关的非参数分布。我们使用了对58例因医院获得性肺炎接受750mg剂量左氧氟沙星治疗的患者进行分析得到的分布。通过使用ADAPT II将参数向量及其相关概率的集合输入到D最优设计评估中。按概率加权的采样时间以频率直方图显示(这表达了群体系统信息随时间的变化情况)。这种信息时间分布的明确表达允许进行合理的采样设计,该设计不仅像传统D最优设计理论那样对群体均值向量稳健,而且对总体的大部分也稳健。对于左氧氟沙星,一个合理的六样本设计是在开始90分钟输注后的1.5、2、2.25、4、4.75和24小时。这种采样设计允许在最大后验概率贝叶斯步骤之后进行有信息量的群体药代动力学分析,并获得精确且无偏的估计。这使得描绘药效学关系的概率最高。